In the management of T2D and obesity, glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) have evolved into cornerstone therapy [4]. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.